Insights
Insights From Our Experts
Articles
Are You Benchmarking Your PSP Against Others? If So, Who and What Are You Comparing It Against?
Many of our clients are looking for ways to ensure their Patient Support Program (PSP) is not only serving their patient and provider populations well but that it is doing so in a fiscally responsible way.…
Informing NAMs Payer Strategies and Improving Contracts With Integrated Commercial Services
Pharmaceutical manufacturers rely on national account managers (NAMs) to build relationships, negotiate contracts and get their products in front of payers and pharmacy benefit managers who will clear the way for patient treatment coverage. Challenges Facing…
Revolutionizing FRMs With Data Connectivity and Commercial Services Integration
FRMs, sometimes referred to as field reimbursement specialists or patient experience specialists, are the key drivers in patient pre-authorization and billing and coding processes, and play a vital role in the prescription and adoption of specialty…
3 Ways Field Teams Can Shape the Market Before and After Product Launch
“It is not how much you have or know, or even who you know; it is how well you adapt to the inevitable changes along the way. As Heraclitus, the Greek philosopher, said, ‘Change is the…
Navigating Payer Formularies and Meeting Payer Needs — and Why It Matters
In a market where all healthcare stakeholders expect more from manufacturers, payers are no exception. As payers work to support patients and meet their own industry needs, manufacturers need to understand payer processes to improve patient…
News Alert: MCIT Program Delayed Until December
The Centers for Medicare and Medicaid Services (CMS) again delayed implementation of the Medicare Coverage of Innovative Technology (MCIT) program, now until December 15, 2021. The program, as described in the current and preceding rules, will…
Gross-To-Net: Challenges and Best Practices
The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization and underutilization. Moving forward, the more diligent payers…
Breaking Up Is Hard to Do: When to Leave Your CRO for Optimized Pharmacovigilance
During an intense year for biopharma innovation, the industry’s rapid growth is spotlighting a global need to bring pharmacovigilance practices up to speed. Executing superior pharmacovigilance practices from clinical trials throughout the product life cycle is…
Pharma’s Push and Pull: Products Approved Amid Government Pushes for Regulation and Pricing Change: April 2021
Global healthcare and life sciences innovation continues to surge at an unprecedented rate, and government entities worldwide are trying to keep up. Price transparency and treatment affordability remain at the top of the list for legislative concern. For instance, United States…
The Secret’s Out: The Impact of Net Price Transparency
Pricing system pressures are increasing for the top four markets in Europe. Price transparency, changes to public health plans and curative therapies are set to disrupt traditional drug pricing. To navigate this ever-shifting landscape, companies must…